期刊
ALLERGY
卷 73, 期 9, 页码 1860-1870出版社
WILEY
DOI: 10.1111/all.13438
关键词
asthma patient; glucocorticoid; group 2 innate lymphoid cells; inhibition; STAT signalling pathway
资金
- NSFC for Excellent Young Scholars/NSFC [81322012, 81373174, 81471832, 81470674, 81671882, 81671611, 81770984, 81770024]
- Science and Technology Foundation of Guangdong Province of China [2015B020225001]
- Natural Science Foundation of Guangdong Province [2014A030313051, 2016A030308017, 2017A030313105]
BackgroundGroup 2 innate lymphoid cells (ILC2s) were closely associated with asthma. However, there were no perspective studies about the effects of glucocorticoid on ILC2s in asthma patients. Our objective was to perform a perspective study and evaluate the ILC2 activity after glucocorticoid therapy in asthma patients. MethodsThe asthma and asthma with allergic rhinitis patients were treated with glucocorticoid for 3months. The circulating ILC2 levels were evaluated. The effects of glucocorticoid on ILC2s and possible signalling pathways were investigated invitro. ResultsThe patients were well-controlled, and the high ILC2 levels were significantly decreased at 1 and 3months after treatment. Peripheral blood monocytes from allergic patients produced dramatic IL-5, IL-13 and IL-9 in response to IL-25, IL-33 plus IL-2, and glucocorticoid significantly decreased their levels. Moreover, ILC2s were identified to be the predominant source of IL-5, IL-13 and IL-9, and glucocorticoid treatment was able to reverse their high levels. STAT3, STAT5, STAT6, JAK3 and MEK signalling pathways were proved to be involved in regulating ILC2 activity under the glucocorticoid treatment. ConclusionThe data suggested that glucocorticoid administration could be effective in treating asthma by regulating ILC2s via MEK/JAK-STAT signalling pathways. This provides a new understanding of glucocorticoid application in regard to allergic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据